Artiva Biotherapeutics, Inc. (ARTV)

In our clinic, evaluating the EULAR 2026 data for AlloNK alongside rituximab in refractory rheumatoid arthritis has been quite illuminating. The observed deep B-cell depletion coupled with a favorable outpatient tolerability profile gives us strong conviction regarding its therapeutic positioning heading into the upcoming Phase 3 trial.

On our desk, we are closely tracking the aftermath of the May 2026 public offering. While the $300 million gross capital raise successfully fortified the balance sheet—pushing cash reserves to $349.4 million—the initial 9% discount on the offering temporarily weighed on pre-market momentum and highlights ongoing dilution sensitivity among retail and institutional holders.

Looking at the quantitative valuation models, our risk management group notes a divergence between fundamental clinical milestones and quantitative pricing metrics. With the CirclFi valuation models pointing toward a moderate quality score and cautious near-term upside, we are maintaining strict stop-loss parameters around ARTV.

From a regulatory standpoint, securing the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for AlloNK plus rituximab is a major institutional validator. Alignment on a single Phase 3 registrational trial involving approximately 150 refractory RA patients streamlines the clinical path forward significantly.

On our options desk, we are evaluating the expiration of the lock-up agreements on August 7, 2026, covering specific restricted stock units and stock options. Potential insider share release combined with historical volatility following major capital raises suggests implementing hedged option strategies rather than naked directional exposure.